ClinicalTrials.gg
Active, not recruitingNCT05530174ProHipQ-FUpdated Mar 24, 2025

Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture

An interventional study of Antibiotic dosage practice in Fracture of Hip, Total Hip Arthroplasty and Prosthetic-joint Infection, sponsored by Soren Overgaard. Active, not recruiting at 36 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Soren Overgaard · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Hip Fractures with a site in Denmark — 8 open to participants now, 10 under way, none of them phase 3. Hip Fractures · Denmark.

Planned enrollment
2nd of 45
2,000 · median 90
Started
2022
the only one that year
No phase
22 of 57
5 open now
Registered
44th of 57
by date
Lead sponsor
2 of 57
Soren Overgaard

Among the 57 studies in Hip Fractures with a site in Denmark, this one is the 2nd largest by planned enrollment of the 45 interventional ones that give a count, is the only one that started in 2022, is one of 22 with no phase, and was the 44th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

8 of the 57 studies in Hip Fractures with a site in Denmark are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hip Fractures with a site in Denmark, or all of them as a file.
02

Study summary

Aim: To compare the effect of one single dose versus multiple doses of prophylactic antibiotics administered within 24 hours, on the development of PJI after surgery in patients undergoing primary THA due to an acute fracture or sequelae of proximal femoral or acetabular fractures.

The study is designed as a cross-over, cluster randomized, non-inferiority trial. All Danish orthopedic surgery departments performing primary THA with the majority being within inclusion criteria will be involved: Based on national quality databases, two-year cohorts of approximately 2,000 primary THAs due to a fracture or sequelae to a fracture, conducted at all public and private orthopedic departments in Denmark, this includes 36 sites corresponding to a total of 39 departments.

Read the detailed description

The outcome measures will be extracted from the following national databases: The Civil Registration System (CRS), The Danish Hip Arthroplasty Register (DHR), The Danish National Patient Registry (DNRP), The Hospital Acquired Infections Database (HAIBA), The Danish National Prescription Database (NPR), Statistics Denmark and Danish Agency for Labour Market and Recruitment registry (STAR).

Details regarding the Arms and Interventions:

The preoperative dose of antibiotic must be administered prior to surgical incision and in cases of delay with regards to planned surgical incision:

Dicloxacillin/Cloxacillin: If the preoperative antibiotic dose is administered >60 minutes prior to surgical incision, the initial dose must be repeated.

Cefuroxime: If the preoperative antibiotic dose is administered >90 minutes prior to surgical incision, the initial dose must be repeated.

Treatment A, Single-dose practice:

For patients ≥ 120 kg:

One preoperative single dose of either Dicloxacillin/Cloxacillin 3g OR Cefuroxime 3g administered intravenously prior to surgical incision.

In cases of cephalosporin allergy or general beta lactam allergy one preoperative single dose of Clindamycin 900mg administered intravenously, prior to surgical incision, regardless of weight.

Treatment B, Multiple-dose practice:

For patients ≥ 120 kg:

One preoperative single dose of either Dicloxacillin/Cloxacillin 3g OR Cefuroxime 3g administered intravenously prior to surgical incision, followed by 3 postoperative doses of Dicloxacillin/Cloxacillin 2g x 3 OR cefuroxime 1.5g x 3, administered within 24 hours after the preoperative dose, corresponding to 6, 12 and 18 hours postoperatively.

After the first postoperative dose, the remaining doses may be administered perorally for pragmatic reasons.

Dicloxacillin p.o. 1g, 12 and 18 hours postoperatively. OR Amoxicillin and clavulanic acid p.o. 875mg/125*mg, 12 and 18 hours postoperatively.

*If the center or region does not have access to amoxicillin and clavulanic acid 875/125mg a dose of 1g / 125mg (this means amoxicillin 500mg + amoxicillin and clavulanic acid 500mg/125 mg) may be administered.

In cases of cephalosporin allergy or general beta lactam allergy one preoperative single dose of Clindamycin 900mg administered intravenously, prior to surgical incision, regardless of weight, followed by 2 postoperative doses corresponding to:

For patients \<120kg: 300mg, 8 and 16 hours postoperatively. For patients ≥ 120kg: 600mg, 8 and 16 hours postoperatively. The same doses apply in cases of transmission to peroral antibiotics.

Implementation: The senior biostatistician is responsible for the randomization process of the centers. Each center will be allocated a code by the senior biostatistician responsible and reported to a central database. The randomization and allocation procedure will be known for the given year conditioning the given center.

Ethics and Dissemination: This trial has been approved by the Regional Ethical Committee (VEK) (21069108) and The Danish Medicines Agency (2021091723) without imposing an obligation to notify.

03

Conditions studied

  • Fracture of Hip
  • Total Hip Arthroplasty
  • Prosthetic-joint Infection
  • Fracture Acetabular

Browse trials for

Keywords

  • Antibiotic Prophylaxis
  • Hip Fracture
  • Acetabular Fracture
  • Total Hip Replacement
  • Total Hip Arthroplasty
  • Prosthetic Joint Infection
  • PJI
  • Cluster Randomized Controlled Trial
  • Randomized Controlled Trial
  • RCT
  • THA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients receiving a primary Total Hip Arthroplasty (THA) due to an acute- or sequelae of proximal femoral or acetabular fractures

Exclusion criteria

Exclusion Criteria:

  • Patients receiving a primary THA due to bone tumor or
  • Patients receiving a primary THA due to osteoarthritis and all reasons according to the Danish Hip Arthroplasty Register (DHR) except conditions mentioned in the inclusion criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Treatment A, Single-dose practice

    One preoperative single dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision. As the study is a non-inferiority trial, we have chosen the Experimental design category.

    Other: Antibiotic dosage practice

  • Active comparator
    Treatment B, Multiple-dose practice

    One preoperative dose of either Dicloxacillin/Cloxacillin 2g OR Cefuroxime 1.5g administered intravenously prior to surgical incision followed by 3 postoperative doses of Dicloxacillin/Cloxacillin 1g x 3 OR Cefuroxime 750mg x 3 within 24 hours after the preoperative dose.

    Other: Antibiotic dosage practice

Interventions

  • OtherAntibiotic dosage practice

    Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years. All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered. In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines.

06

What researchers measure

Primary outcomes

  1. Incidence of Prosthetic joint infections (PJI)

    The definition of PJI is based on revision surgery. Revision surgery is defined as a new surgical intervention the first time after the primary intervention including debridement alone or in combination with complete or partial removal or exchange of the implant. The definition of PJI is based on revision surgery. Revision surgery is defined as a new surgical intervention the first time after the primary intervention including debridement alone or in combination with complete or partial removal or exchange of the implant. 1. Two or more intraoperative deep-tissue samples of phenotypically indistinguishable bacteria isolated from at least 3 deep-tissue samples 2. One or more positive intraoperative samples from a closed fluid aspirate AND a biopsy (fluid AND tissue) of phenotypically indistinguishable bacteria isolated 3. A PJI when an indication of deep infection is reported to The Danish Hip Arthroplasty Registry (DHR) by the surgeon upon revision surgery

    Time frame: Within 90 days from index surgery

Secondary outcomes

  1. Number of patients with one or more Serious Adverse Events (SAEs)

    SAEs are defined according to the ICH-GCP guidelines. SAE refers to an event involving a significant risk of death or disability of the patient (or their offspring), including, but not limited to, an event that: * results in death * is life-threatening - in the investigator's opinion the patient was in immediate risk of death from the adverse event when it appeared * requires hospitalization or prolongs existing hospitalization * results in permanent or significant disability * is a congenital anomaly SAEs are recorded from The Danish National Patient Registry (DNPR).

    Time frame: Within 90 days from index surgery

  2. Incidence of Potential PJI referred to as PJI-likely

    PJI-likely is defined as at least one of the two criteria: 1. One single intraoperatively obtained positive culture (aspiration fluid OR tissue biopsy) regardless of microorganism 2. One single positive culture obtained from aspiration of synovial fluid regardless of microorganism AND any antibiotic prescriptions (ATC category J01) redeemed

    Time frame: Within 90 days from index surgery

  3. Length of hospital stay (LOS)

    LOS defined as number of postoperative overnight stays, including transferals to other departments and hospitals. Data on LOS is acquired from DNPR.

    Time frame: Within 90 days from index surgery

  4. Incidence of Major Adverse Cardiovascular Events (MACE)

    A MACE is defined a priori to include thromboembolic complications including venous thromboembolism, myocardial infarction, atrial fibrillation and stroke based on the diagnostic ICD10 codes listed in Appendix B. VTE is defined a priori as both deep venous thromboembolisms confirmed by compression ultrasound and pulmonary embolism confirmed by spiral computed tomography (CT), ventilation-perfusion scintigraphy or pathological removal of an embolus and based on the following diagnostic ICD10 codes: I26, I80.1-I80.9, I82.1-I82.9, or T81.7B-D. Data will be extracted from DNPR.

    Time frame: Within 90 days from index surgery

  5. Hospital-treated infections (excluding Surgical Site infections)

    Any Hospital-treated infection is defined as any first-time hospital admission with a primary or secondary infection diagnosis after discharge from index THA surgery. Hospital-treated infections are identified from DNPR. The list of infections includes chronic and more rare infections, to detect possible flare-up in any possible ongoing infections. The list will exclude urinary tract infections (UTI) due to a high risk of different registration praxis registration for UTI among hospitals in Denmark.

    Time frame: Within 90 days from index surgery

  6. Proportion of patients with at least one dispensing for antibiotic

    Community-based antibiotic use (any community-treated infection or antibiotic use after discharge) is defined as at least one dispensing after discharge from index THA surgery within 90 days for narrow- and broad-spectrum antibiotics based on the Anatomical Therapeutic Chemical classification (ATC) codes. All antibiotics in Denmark require prescriptions from a physician. The Danish National Health Service Prescription Database has registered all reimbursed prescriptions from all community pharmacies since 2004. Medications are coded according to the following ATC codes: J01CE, J01CF, J01DB, J01DC, J01DD, J01DE, J01DH, J01DI, J01CR, J01CA, J01F. J01E, J01MA ,J01AA

    Time frame: Within 90 days from index surgery

  7. Opioid use

    Prescriptions will be identified using NPR. The following ATC codes (including all subcodes) are included: N01AH (opioid anesthetics), N02A (opioids), N07BC02 (methadone), and R05DA04 (codeine). We defined opioid users as patients who redeemed two opioid prescriptions within six months prior to THA surgery. Conversely, patients who did not redeem two or more opioid prescriptions within this timeframe were classified as opioid naïve. For opioid naïve patients, opioid use post-THA is defined as the redemption of two opioid prescriptions within 90 days following surgery. We assert that two separate redeemed prescriptions confirm actual medication use. We will calculate the treatment dosage based on the number of packages and volume redeemed within 90 days post-surgery. To investigate dosages, all doses will be converted to morphine milligram equivalents using a conversion factor specific to the type of opioid.

    Time frame: Within 90 days from index surgery

  8. Use of acetaminophen or non-steroidal anti-inflammatory drugs

    Patients who received at least one prescription for acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) following THA surgery. Prescriptions of analgesics will be identified using NPR (41). All analgesics in Denmark except 10-tablet packages of acetaminophen / ibuprofen of dose 200mg ibuprofen require prescriptions from a physician. Following ATC codes (including all subcodes) are included M01A (NSAIDs) and N02BE01 (paracetamol). Duration of treatment will be calculated based on number of packages and volume. Since there is no clear definition of acetaminophen or non-steroidal anti-inflammatory users, we define these users as patients who redeemed two prescriptions within 6 months before THA.

    Time frame: Within 90 days from index surgery

  9. Any revision after THA

    Revision surgery is defined as a new surgical intervention the first time after the primary intervention including debridement alone or in combination with complete or partial removal or exchange of any implants. Rate of revision is defined as revision due to any cause within 90 days from primary THA surgery. Any revision will be recorded from DHR and DNPR.

    Time frame: Within 90 days from index surgery

Other outcomes

  1. Incremental cost-effectiveness

    The incremental cost-effectiveness will be calculated based on the costs per patient in the two antibiotic practices. Costs related to antibiotic prophylaxis, hospital admissions and readmissions, hospital outpatient visits, visits to General practitioner and costs related to sick leave from work will be included. Data will be collected from: * The Danish National Patient Registry (DNPR) * The Civil Registration System (CRS) * The Danish Agency for Labor Market and Recruitment registry STAR

    Time frame: Within 90 days from index surgery

  2. Rate of revision after THA

    Revision surgery is defined as a new surgical intervention the first time after the primary intervention including debridement alone or in combination with complete or partial removal or exchange of the implant. Revision due to any cause including PJI and aseptic loosening are included. Revision risk is recorded from DHR and DNPR.

    Time frame: Within 1 year from index surgery

  3. Mortality rate after index surgery

    1-year mortality rate is defined by date of death due to any cause after index surgery. Data is collected from The Civil Registration System (CRS).

    Time frame: Within 1 year from index surgery

  4. Incidence of Superficial incisional Surgical Site Infection

    To be defined

    Time frame: Within 90 days from index surgery

07

Study locations

36 sites
  • Department of Orthopedic Surgery, Aabenraa and Sønderborg, Hospital of Southern Jutland
    Aabenraa, 6200/6400, Denmark
  • Capio Private Hospital, Aalborg
    Aalborg, 9000, Denmark
  • Department of Orthopedic Surgery, Aalborg, Aalborg University Hospital
    Aalborg, 9000, Denmark
  • Capio Private Hospital, Aarhus
    Aarhus C, 8000, Denmark
  • Aleris Private Hospital, Aarhus
    Aarhus, 8200, Denmark
  • Deaprtment of Orthopaedic Surgery, Aarhus University Hospital
    Aarhus, 8200, Denmark
  • Capio Private Hospital, Gildhøj
    Brøndby, 2605, Denmark
  • Department of Orthopedic Surgery and Traumatology, Bispebjerg, Copenhagen University Hospital - Bispebjerg and Frederiksberg
    Copenhagen NV, 2400, Denmark
  • Adeas Private Hospital, Parken
    Copenhagen Ø, 2100, Denmark
  • Department of Orthopedic Surgery, Esbjerg, Hospital of South West Jutland
    Esbjerg, 6700, Denmark
  • Department of Orthopedic Surgery, Farsø, Aalborg University Hospital
    Farsø, 9640, Denmark
  • CPH Private Hospital
    Farum, 3520, Denmark
  • Department of Orthopedic Surgery, Frederikshavn, Aalborg University Hospital
    Frederikshavn, 9900, Denmark
  • Department of Orthopedic Surgery, Grindsted, Hospital of South West Jutland
    Grindsted, 7200, Denmark
  • Capio Private Hospital, Hellerup and Odense
    Hellerup, 2900/5000, Denmark
  • Department of Orthopaedic Surgery, Gentofte, Copenhagen University Hospital - Herlev and Gentofte
    Hellerup, 2900, Denmark
  • Department of Orthopaedic Surgery, Herlev, Copenhagen University Hospital - Herlev and Gentofte
    Herlev, 2730, Denmark
  • Department of Orthopedic Surgery, Gødstrup Regional Hospital
    Herning, 7400, Denmark
  • Department of Orthopedic Surgery, Hillerød, Copenhagen University Hospital - North Zealand
    Hillerød, 3400, Denmark
  • Department of Orthopedic Surgery, Copenhagen University Hospital - Holbæk
    Holbæk, 4300, Denmark
  • Department of Orthopedic Surgery, Horsens Regional Hospital, Denmark
    Horsens, 8700, Denmark
  • Department of Orthopedic Surgery, Hvidovre, Copenhagen University Hospital - Amager and Hvidovre
    Hvidovre, 2650, Denmark
  • Acure Private Hospital
    Kongens Lyngby, 2800, Denmark
  • Kollund Private Hospital, Kollund
    Kruså, 6340, Denmark
  • Department of Orthopedic Surgery, Zealand University Hospital, Køge
    Køge, 4600, Denmark
  • Department of Orthopedic Surgery, Copenahegn University Hospital - Nykøbing F.
    Nykøbing Falster, 4800, Denmark
  • Department for Planned Orthopaedic Surgery, Næstved, Copenhagen University Hospital - Næstved, Slagelse and Ringsted
    Næstved, 4700, Denmark
  • Department of Orthopedic Surgery and Traumatology, Odense University Hospital and Svendborg Hospital
    Odense, 5000/5700, Denmark
  • Deparmtent of Orthopedic Surgery, Randers Regional Hospital
    Randers, 8930, Denmark
  • Aleris Private Hospital, Ringsted
    Ringsted, 4100, Denmark
  • Department of Surgery, Copenhagen University Hospital - Bornholm
    Rønne, 3700, Denmark
  • Center for Planned Surgery, Silkeborg Regional Hospital
    Silkeborg, 8600, Denmark
  • Aleris Private Hospital, Søborg
    Søborg, 2860, Denmark
  • Department of Orthopedics, Lillebaelt Hospital, Vejle
    Vejle, 7100, Denmark
  • Mølholm Private Hospital, Vejle
    Vejle, 7100, Denmark
  • Deparmtent of Orthopedic Sugery, Viborg Regional Hospital
    Viborg, 8800, Denmark
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), will be provided to anyone who wishes to access the data.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Immediately following publication, no end date.

Access criteria: Anyone who wishes to access the data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Apr 2025, 31 months after the start.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 31 months is above that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2022
First posted
Sep 7, 2022
StartActual
Sep 1, 2022
Primary completionEst.
Apr 1, 2025
CompletionEst.
Apr 1, 2025
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05530174
Lead sponsor
Soren Overgaard
Collaborators
University of Copenhagen, University Hospital Bispebjerg and Frederiksberg, Odense University Hospital, Aarhus University Hospital, University of Aarhus, Sygehus Lillebaelt
Responsible party
Soren Overgaard (Clinical Professor, DMSc, University Hospital Bispebjerg and Frederiksberg) — Sponsor-investigator
First posted
Sep 7, 2022
Start date
Sep 1, 2022
Primary completion
Apr 1, 2025 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Mar 24, 2025

Study contacts

Armita A Abedi, MD
principal investigator · Copenhagen University Hospital, Bispebjerg Department of Orthopedic Surgery and Traumatology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion